Solventum beats Q1 earnings & revenue estimates, raises sales guidance, remains optimistic

From Nasdaq: 2025-05-09 09:45:00

Solventum (SOLV) reported first-quarter 2025 adjusted earnings per share of $1.34, beating estimates by 12.6%. However, the bottom line decreased by 35.6% year over year. Revenues were $2.07 billion, up 2.6% from the prior year, with organic sales growth of 4.3%. MedSurg segment revenues were up 3.4% to $1.16 billion.

Shares of Solventum rose 1.4% after-hours, with a 20.8% increase since its IPO. The company raised its 2025 sales guidance and expects organic sales growth of 1.5-2.5%. Despite a decline in adjusted EPS, the company remains optimistic about its long-term prospects and ongoing restructuring efforts.

Segment-wise, Solventum saw growth in MedSurg, HIS, Dental Solutions, and Purification and Filtration segments. Margins declined, with adjusted gross margin at 55.6% and adjusted operating margin at 19.7%. The company exited Q1 with $534 million in cash and investments.

Solventum remains a top pick with a Zacks Rank #2 (Buy). Other top-ranked stocks in the medical industry include AxoGen (AXGN), Cardinal Health (CAH), and CVS Health (CVS). AxoGen has an estimated growth rate of 76.9% for 2025, while Cardinal Health and CVS Health have also shown strong performance.

Solventum’s strong performance in Q1, along with positive growth projections and ongoing restructuring efforts, indicate a promising future for the company. With a focus on debt reduction and operational efficiency, Solventum is well-positioned for continued success in the medical industry.



Read more at Nasdaq: Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline